Chuck Royce's TRDA Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 120,845 shares of Entrada Therapeutics, Inc. (TRDA) worth $1.53 M, representing 0.02% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 4 quarters.
Based on 13F filings, Chuck Royce has maintained this position in TRDA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 122,256 shares. Largest reduction occurred in Q1 2026, reducing 126,302 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Entrada Therapeutics (TRDA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Entrada Therapeutics (TRDA) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -126,302 | Reduce 51.10% | 120,845 | $12.62 |
| Q4 2025 | -98,360 | Reduce 28.47% | 247,147 | $10.28 |
| Q3 2025 | +122,256 | Add 54.76% | 345,507 | $5.80 |
| Q2 2025 | +223,251 | New Buy | 223,251 | $6.72 |
Chuck Royce's Entrada Therapeutics Investment FAQs
Chuck Royce first purchased Entrada Therapeutics, Inc. (TRDA) in Q2 2025, acquiring 223,251 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Entrada Therapeutics, Inc. (TRDA) for 4 quarters since Q2 2025.
Chuck Royce's largest addition to Entrada Therapeutics, Inc. (TRDA) was in Q2 2025, adding 223,251 shares worth $1.5 M.
According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 120,845 shares of Entrada Therapeutics, Inc. (TRDA), valued at approximately $1.53 M.
As of the Q1 2026 filing, Entrada Therapeutics, Inc. (TRDA) represents approximately 0.02% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Entrada Therapeutics, Inc. (TRDA) was 345,507 shares, as reported at the end of Q3 2025.